Tumor Heterogeneity and Consequences for Bladder Cancer Treatment

Acquired therapeutic resistance remains a major challenge in cancer management and associates with poor oncological outcomes in most solid tumor types. A major contributor is tumor heterogeneity (TH) which can be influenced by the stromal; immune and epithelial tumor compartments. We hypothesize tha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Etienne Lavallee, John P. Sfakianos, David J. Mulholland
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	bladder cancer plasticity intratumoral heterogeneity treatment resistance tumoral heterogeneity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/72c5d52292834519b11dd8987ebe4ef7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:72c5d52292834519b11dd8987ebe4ef7
record_format	dspace
spelling	oai:doaj.org-article:72c5d52292834519b11dd8987ebe4ef72021-11-11T15:27:33ZTumor Heterogeneity and Consequences for Bladder Cancer Treatment10.3390/cancers132152972072-6694https://doaj.org/article/72c5d52292834519b11dd8987ebe4ef72021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5297https://doaj.org/toc/2072-6694Acquired therapeutic resistance remains a major challenge in cancer management and associates with poor oncological outcomes in most solid tumor types. A major contributor is tumor heterogeneity (TH) which can be influenced by the stromal; immune and epithelial tumor compartments. We hypothesize that heterogeneity in tumor epithelial subpopulations—whether de novo or newly acquired—closely regulate the clinical course of bladder cancer. Changes in these subpopulations impact the tumor microenvironment including the extent of immune cell infiltration and response to immunotherapeutics. Mechanisms driving epithelial tumor heterogeneity (EpTH) can be broadly categorized as mutational and non-mutational. Mechanisms regulating lineage plasticity; acquired cellular mutations and changes in lineage-defined subpopulations regulate stress responses to clinical therapies. If tumor heterogeneity is a dynamic process; an increased understanding of how EpTH is regulated is critical in order for clinical therapies to be more sustained and durable. In this review and analysis, we assess the importance and regulatory mechanisms governing EpTH in bladder cancer and the impact on treatment response.Etienne LavalleeJohn P. SfakianosDavid J. MulhollandMDPI AGarticlebladder cancerplasticityintratumoral heterogeneitytreatment resistancetumoral heterogeneityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5297, p 5297 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bladder cancer plasticity intratumoral heterogeneity treatment resistance tumoral heterogeneity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	bladder cancer plasticity intratumoral heterogeneity treatment resistance tumoral heterogeneity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Etienne Lavallee John P. Sfakianos David J. Mulholland Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
description	Acquired therapeutic resistance remains a major challenge in cancer management and associates with poor oncological outcomes in most solid tumor types. A major contributor is tumor heterogeneity (TH) which can be influenced by the stromal; immune and epithelial tumor compartments. We hypothesize that heterogeneity in tumor epithelial subpopulations—whether de novo or newly acquired—closely regulate the clinical course of bladder cancer. Changes in these subpopulations impact the tumor microenvironment including the extent of immune cell infiltration and response to immunotherapeutics. Mechanisms driving epithelial tumor heterogeneity (EpTH) can be broadly categorized as mutational and non-mutational. Mechanisms regulating lineage plasticity; acquired cellular mutations and changes in lineage-defined subpopulations regulate stress responses to clinical therapies. If tumor heterogeneity is a dynamic process; an increased understanding of how EpTH is regulated is critical in order for clinical therapies to be more sustained and durable. In this review and analysis, we assess the importance and regulatory mechanisms governing EpTH in bladder cancer and the impact on treatment response.
format	article
author	Etienne Lavallee John P. Sfakianos David J. Mulholland
author_facet	Etienne Lavallee John P. Sfakianos David J. Mulholland
author_sort	Etienne Lavallee
title	Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
title_short	Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
title_full	Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
title_fullStr	Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
title_full_unstemmed	Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
title_sort	tumor heterogeneity and consequences for bladder cancer treatment
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/72c5d52292834519b11dd8987ebe4ef7
work_keys_str_mv	AT etiennelavallee tumorheterogeneityandconsequencesforbladdercancertreatment AT johnpsfakianos tumorheterogeneityandconsequencesforbladdercancertreatment AT davidjmulholland tumorheterogeneityandconsequencesforbladdercancertreatment
_version_	1718435245212041216

Tumor Heterogeneity and Consequences for Bladder Cancer Treatment

Ejemplares similares